Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Efficacy, Safety And Tolerability Of Three Treatment Regiments For Uncomplicated Falciparum Malaria: Artesunate (3 Days) + Amodiaquine (3 Days) Vs. Art?sunate (3 Days) + Sulfadoxine-Pyrim?thamine (1day) Vs. Art?sunate (5 Days)

Trial Profile

Comparative Efficacy, Safety And Tolerability Of Three Treatment Regiments For Uncomplicated Falciparum Malaria: Artesunate (3 Days) + Amodiaquine (3 Days) Vs. Art?sunate (3 Days) + Sulfadoxine-Pyrim?thamine (1day) Vs. Art?sunate (5 Days)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2018

At a glance

  • Drugs Artesunate (Primary) ; Artesunate/amodiaquine (Primary) ; Artesunate/pyrimethamine/sulfadoxine (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi-Synthelabo
  • Most Recent Events

    • 26 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top